Holden Leads Blog

Cannabis Industry Insights

Data, outreach strategies, and market intelligence for cannabis B2B professionals.

June 2, 2026

The DEA Hearing Is Six Weeks Away. Here's What That Actually Means for Cannabis.

The clock is now running on one of the most consequential proceedings in American drug policy history. The Drug Enforcement Administration's formal hearing on whether to reschedule marijuana from Schedule I to Schedule III of the Controlled Substances Act is officially set to begin.

Read more →
June 1, 2026

Curaleaf's Stock Move, New York's $3.3 Billion Milestone, and the Rise of the Digital Dispensary Shopper

The cannabis industry had a week of quiet but consequential momentum, driven less by splashy announcements than by the accumulating weight of numbers that are starting to tell a coherent story: markets are maturing, winners are consolidating their positions, and the question of who survives the next two years is coming into sharper focus.

Read more →
May 29, 2026

THC Drinks at Target, Dab Rig Popcorn Buckets, and the Race to Normalize Cannabis

There are two ways to know that cannabis has gone fully mainstream. One is when the federal government reschedules it. The other is when you can buy a THC seltzer at Target while picking up toilet paper — in Texas.

Read more →
May 28, 2026

Virginia's Governor Says No — And the Industry Watches What Comes Next

Virginia Governor Abigail Spanberger's decision this week to veto legislation creating the state's first licensed adult-use cannabis retail market is, on one level, a familiar story: a governor and a legislature disagreeing over the details of a cannabis bill.

Read more →
May 27, 2026

From Pain Pills to Pain Relief — A Week of Science That Demands Attention

A new study from researchers at the University of Pennsylvania found that patients using medical cannabis for chronic pain reduced their opioid consumption by an average of 65% over a five-month follow-up — with seven of 29 participants stopping opioid therapy entirely.

Read more →
May 26, 2026

The Lawsuit That Could Reshape the Entire MSO Business Model

The cannabis industry has spent years arguing it deserves to be treated like any legitimate business. This week, it got exactly what it asked for — in the form of a 320-page federal complaint invoking the same legal framework that took down the mob.

Read more →
May 21, 2026

Cannabis and the Aging Brain: New Research Complicates the Picture in Productive Ways

Two significant studies landed within days of each other, each rigorous, each credible, each pointing in a subtly different direction — and together they illustrate exactly why the science of cannabis and cognition is so difficult to summarize in a headline.

Read more →
May 20, 2026

Big Box THC: Target's Beverage Bet Is Either a Masterstroke or a Gamble, Depending on November

a brand synonymous with suburban family shopping trips, dollar-bin treasures, and Starbucks kiosks near the entrance — quietly stocking its shelves with intoxicating products that, in a dispensary, would require an ID check and a brief tutorial on onset times.

Read more →
May 19, 2026

The Deadline Is Coming: Cannabis Operators Brace for a Pivotal Spring in Federal Policy

The calendar on the wall of every cannabis lobbyist's office is circled in red on two dates this spring: May 24 and June 29. They mark, respectively, the deadline to formally request participation in the most consequential federal cannabis rulemaking in history, and the day the hearing actually begins.

Read more →
May 18, 2026

Schedule III Aftershocks: How Rescheduling Is Reshaping the Business of Cannabis

Controlled Substances Act — an action that technically changed nothing about what's legal where, but is rapidly changing everything about how cannabis companies operate, report earnings, and plan their futures.

Read more →